Table 2 Association between the CTLA-4+ cell density (cells/mm2) as well as the CTLA4/CD3-ratio and clinicopathological parameters.
Characteristic | Patient number (%) | CTLA4+ cell density | p value | Patient number (%) | CTLA4/CD3-ratio | p value |
|---|---|---|---|---|---|---|
Total | 4582 | 673 (±1482) median: 214 | 4292 | 17 (±52) median: 2 | ||
Pathological tumor stage | <0.0001 | 0.1846 | ||||
pT1 | 763 (16.7%) | 410 (±570) | 740 (17.2%) | 20 (±56) | ||
pT2 | 746 (16.3%) | 350 (±467) | 714 (16.6%) | 18 (±46) | ||
pT3 | 839 (18.3%) | 273 (±364) | 710 (16.5%) | 16 (±39) | ||
pT4 | 341 (7.4%) | 306 (±345) | 328 (7.6%) | 15 (±30) | ||
Missing data | 1893 (41.3%) | - | 1800 (41.9%) | - | ||
Pathological nodal stage | 0.0031 | 0.0354 | ||||
pN− | 839 (18.3%) | 373 (±491) | 794 (18.5%) | 21 (±55) | ||
pN+ | 1003 (21.9%) | 312 (±398) | 962 (22.4%) | 16 (±37) | ||
Missing data | 2740 (59.8%) | - | 2536 (59.1%) | - | ||
PD-L1 on tumor cells | <0.0001 | 0.0026 | ||||
Negative | 2583 (56.4%) | 628 (±1382) | 2498 (58.2%) | 16 (±49) | ||
Positive | 662 (14.4%) | 920 (±1744) | 605 (14.1%) | 23 (±64) | ||
Missing data | 1337 (29.2%) | - | 1189 (27.7%) | - | ||
PD-L1 on immune cells | <0.0001 | 0.1010 | ||||
Negative | 2063 (45.0%) | 310 (±534) | 2068 (48.2%) | 19 (±59) | ||
Positive | 1371 (29.9%) | 1233 (±2059) | 1231 (28.7%) | 16 (±45) | ||
Missing data | 1148 (25.1%) | - | 993 (23.1%) | - | ||
HPV | 0.0130 | 0.9020 | ||||
Negative | 326 (7.1%) | 393 (±392) | 291 (6.8%) | 25 (±56) | ||
Positive | 243 (5.3%) | 489 (±524) | 221 (5.2%) | 25 (±40) | ||
Missing data | 4013 (87.6%) | - | 3780 (88.0%) | - |
